Mean rates of colorectal cancer (CRC) screening tripled among average-risk individuals 45-49 years old after the U.S.
Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...
On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...
The cuts follow an ongoing wave of staff reductions at big drug companies. Pharma giants have terminated thousands of ...
Investor's Business Daily on MSN5h
Has Consumer Products Giant Bristol-Myers Squibb Kicked Into High Gear?A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?
Bristol-Myers Squibb (BMY) wins FDA nod to expand the U.S. label for its blockbuster immunotherapy Opdivo in lung cancer.
The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...
With a recently acquired FDA nod for its Halozyme Therapeutics-partnered Vyvgat Hytrulo, argenx is looking to take Halozyme’s ...
Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...
Home-based phototherapy for plaque and guttate psoriasis is as effective as office-based phototherapy, results of the ...
WARN notices filed with the state show more job cuts due in the health sector as companies look to cut costs and streamline ...
By leveraging AI, drug developers are moving beyond incremental gains in efficiency and engaging previously undruggable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback